Wyoming’s Stem Cell Freedom Act, SF 48, lets a physician perform non-FDA-approved stem cell therapy only if, among other conditions, the therapy is conducted under a current Institutional Review Board approval or the stem cells qualify as an investigational drug, biological product, or device. Those are two distinct legal pathways, and the Act defines each in a specific way. This post is the operational follow-on to the SF 48 overview: it explains what each pathway requires, how long each takes, and which is realistic for which kind of practice.
TLDR: Wyoming SF 48 offers two routes to satisfy its core condition: a current IRB approval, or qualifying as an investigational drug, biological product, or device, which the Act defines as a product that has completed phase one of a clinical trial and remains under FDA investigation. The IRB route is initiated by the physician through an independent board and is the more realistic path for community practices. The investigational route generally depends on an existing IND or affiliation with a trial sponsor. Both sit alongside the Act’s other conditions, including physician registration. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
This post assumes you have already read the overview of Wyoming SF 48 and its five conditions, available in the Wyoming SF 48 physician guide. Here the focus is narrow: the first condition, and the two ways to satisfy it.
The SF 48 Requirement in Plain Terms
Under W.S. 35-4-1103, the therapy must be conducted in accordance with a current IRB approval or the stem cells must qualify as an investigational drug, biological product, or device. The Act defines that second term with precision: it means a drug, biological product, or device that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the FDA and remains under investigation in a clinical trial. That definition matters, because it is narrower than “anything experimental.” A product that has never entered a phase one trial does not qualify under the Act’s investigational route, which pushes most community practices toward the IRB pathway.
Pathway One: IRB Approval
An Institutional Review Board is a committee constituted and registered under federal law to review, approve, and provide continuing oversight of research involving human subjects. The federal framework is 21 CFR Part 56 and the Common Rule at 45 CFR Part 46. Academic medical centers typically operate their own IRBs; a community physician usually must engage an independent, commercial IRB.
The Act’s own definition of IRB is instructive about what the board must do here. SF 48 describes an IRB as a body that provides initial approval and continuing oversight of the stem cell therapies offered under the Act, including adverse event reporting and approval of the informed consent form used between physician and patient. In other words, the IRB approval is granted for a specific research protocol, not for a physician in general. “Conducted under a current IRB approval” means the specific procedure is part of an active, approved protocol, and the approval must be current at the time of each patient’s treatment.
For a community physician, the sequence is: develop a written research protocol covering the procedure, patient population, risks, monitoring plan, and data collection; apply to an independent IRB such as Advarra, WCG, Solutions IRB, or Salus IRB; complete review, where expedited review often runs a few weeks and full-board review longer; implement the protocol exactly as written, with any deviation requiring amendment approval; and submit continuing review reports on the board’s schedule, typically annually. Because SF 48 takes effect July 1, 2026, a physician who does not already hold an applicable IRB approval faces a tight timeline and should treat initiation as urgent or plan for a later operational start.
Pathway Two: Investigational Status
The second route requires the stem cells to qualify as an investigational drug, biological product, or device under the Act’s definition. In federal practice, investigational products are studied under an Investigational New Drug application (IND) for drugs and biologics, governed by 21 CFR Part 312, or an Investigational Device Exemption (IDE) for devices, governed by 21 CFR Part 812. An IND must be submitted to and accepted by the FDA before a clinical investigation begins.
The practical question is who holds that status. In most cases a pharmaceutical or biotechnology company holds the IND for its product. A physician who wishes to use a company’s product under the company’s IND becomes a clinical investigator, must be listed on the IND, and completes FDA Form 1572, the Statement of Investigator, which commits the investigator to conducting the study under the protocol and applicable regulations. A physician can alternatively submit a physician-sponsored IND, but that carries significant regulatory expertise and ongoing FDA reporting obligations.
A note on alignment with the Act: SF 48’s investigational definition keys on a product that has completed phase one and remains under investigation. That is related to, but not identical to, simply holding an IND. The conservative reading is that a physician relying on this route should be able to document both that the product is under an active FDA investigation and that it has cleared phase one. Where a product’s status is ambiguous, the IRB route is the cleaner path. Identifying companies with active investigational programs and expanded-access policies is aided by the Reagan-Udall Expanded Access Navigator, and the access mechanics are covered in the discussion of expanded access programs.
IRB vs. Investigational Status: Comparison
| Factor | IRB Approval | Investigational Status (IND/IDE backdrop) |
|---|---|---|
| Who initiates | The physician, by developing and submitting a protocol | An IND/IDE sponsor, usually a company; or a physician-sponsored IND |
| What it establishes | An approved research protocol with human-subject oversight | A product under active FDA investigation that has cleared phase one |
| Timeline to establish | Often a few weeks for independent-IRB expedited review | Months to years for a new IND; immediate if joining an existing program |
| Ongoing obligations | Continuing review, amendments, adverse-event reporting to the IRB | FDA reporting, Form FDA 1572, sponsor oversight |
| Most practical for | Community physicians initiating their own protocols | Physicians affiliated with an existing trial sponsor or IND |
| Key federal regulation | 21 CFR Part 56; 45 CFR Part 46 | 21 CFR Part 312 (IND); 21 CFR Part 812 (IDE) |
| Satisfies SF 48? | Yes, if therapy is under the active approved protocol | Yes, if the product meets the Act’s investigational definition |
Where Adipose Tissue Banking Fits
Banking, the harvest and cryopreservation of a patient’s own adipose tissue, is distinct from the therapeutic administration of stem cells. Banking itself is not “stem cell therapy” under SF 48 or the other state laws in this series, and the IRB-or-investigational condition applies at the point of therapeutic use, not at the point of banking. The mechanics of what banking actually involves are covered in the explainer on how adipose tissue banking works, and the science of preservation in how cryopreservation works.
A physician who banks a patient’s tissue today in anticipation of possible future use should document the patient’s intent, because that intent will inform what protocol or investigational framework is needed at the time of any future therapeutic use. Documentation today does not create a pathway; it preserves optionality so that whatever pathway exists later can be pursued cleanly.
Pathway Decision Guide
Start with the threshold question: does the physician intend to administer non-FDA-approved stem cell therapy in Wyoming on or after July 1, 2026? If yes, then ask whether the physician is already a listed investigator under an active IND for the specific product they plan to use. If they are, the next step is to confirm IND status, complete Form 1572 if not already done, verify the product meets the Act’s investigational definition, and proceed under the investigational route. If they are not, the next question is whether the physician already holds an active IRB-approved protocol covering this therapy. If they do, confirm the protocol covers the planned procedure and is current, and proceed under the IRB route. If they do not, the physician must either initiate an independent IRB application immediately, which given the timeline is urgent, or become affiliated with an existing sponsored program. In every branch, the Act’s other conditions still apply, including registration with the Wyoming State Board of Medicine and written informed consent.
Frequently Asked Questions
Is holding an IND the same as satisfying SF 48’s investigational route?
Not exactly. The Act defines the investigational route as a product that has completed phase one and remains under FDA investigation. Holding an IND is the federal mechanism for investigation, but the conservative reading requires documenting that the product also meets the Act’s phase-one-complete criterion. When in doubt, the IRB route is cleaner.
Which pathway is realistic for a solo practice?
For most community physicians not already affiliated with a trial sponsor, the IRB pathway is the more accessible route, because the physician can initiate it directly. The investigational route generally depends on a relationship with an existing IND or program.
Does banking tissue require IRB approval?
No. Banking is preservation of the patient’s own tissue and is not stem cell therapy under the Act. The IRB-or-investigational condition applies at the point of therapeutic use, not at banking, and banking guarantees no future eligibility, access, or benefit.
Key Takeaways
SF 48’s first condition is a fork with two tines, and they are not equally accessible. The IRB pathway is physician-initiated, runs on a timeline measured in weeks for expedited independent review, and is the realistic route for a community practice, but it requires a genuine research protocol with continuing oversight, not a paperwork formality. The investigational pathway tracks the federal IND and IDE machinery and is practical mainly for physicians already tied to a sponsor or program, with the added wrinkle that SF 48 defines investigational status specifically as phase-one-complete and still under FDA investigation. Whichever route a physician chooses, it satisfies only one of the Act’s conditions; registration, the physician-patient relationship, cGMP manufacturing, and written informed consent remain independently required. And banking sits outside this entirely: it is a preservation decision that keeps options open, not a treatment, and it guarantees nothing about future use.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Physicians mapping how tissue preservation fits a future research or investigational framework can contact Save My Fat to discuss the operational side. Service and processing details are available at https://savemyfat.com/pricing/.
Save My Fat partners with L2 Bio for laboratory processing and storage. Requirements under Wyoming SF 48 should be reviewed alongside federal FDA regulations; the Act does not limit the FDA’s authority to enforce federal law.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
